Efficient mass spectrometry data analysis capabilities now available to a broad range of pharmaceutical, industrial biotech, and life science companies
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, and LECO, a global leader in analytical instrumentation and mass spectrometers, have announced their collaboration, which brings to market Genedata Expressionist® MSX software compatibility with LECO High Resolution TOFMS (HRT) instrumentation. Designed for complex sample analysis, LECO’s HRT technology provides acquisition speeds of up to 200 spectra/second, mass resolution up to 100,000 FWHM, and mass accuracy less than 1 ppm. Genedata Expressionist MSX is a comprehensive, end-to-end solution for the analysis of mass spectrometry data generated in metabolomics experiments.
“For LECO customers, it will be a great advantage to be able to utilize Expressionist MSX, together with our HRT platform, in their metabolomics applications,” said Dr. Jeff Patrick, director of Marketed Technology, LECO Separation Science. “We understand the unique challenges of metabolomics, and we are proud to provide instrumentation with the speed, sensitivity, resolution, and data-handling tools necessary to meet these challenges head-on. We look forward to a continued collaboration with Genedata that will effectively leverage our mutual capabilities.”
“With the ability to efficiently process raw MS data from LECO instrumentation, Expressionist MSX will enable scientists to quickly address a wide range of metabolomics questions, capitalizing on the high-performance of HRT output,” noted Dr. Othmar Pfannes, CEO of Genedata. “Our collaboration with LECO empowers researchers and advances innovative discovery in pharmaceutical, industrial biotechnology, and life science companies.”